Akèy › Kansè tete negatif triple › Texas › San Antonio
Etid klinik pou Kansè tete negatif triple nan San Antonio, TX
23 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote San Antonio (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Ap rekriteFaz 1/2
- NEXT Oncology, San Antonio
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Ap rekriteFaz 3
- Texas Oncology - San Antonio ( Site 8001), San Antonio
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Ap rekriteFaz 3
- Mays Cancer Center ( Site 0122), San Antonio
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Texas Oncology - San Antonio ( Site 8004), San Antonio
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, San Antonio
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology - San Antonio, San Antonio
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Texas Oncology, San Antonio
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Ap rekriteFaz 1
- START-San Antonio, San Antonio
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, San Antonio
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- START San Antonio, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Clinical Trial Site, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- START San Antonio, San Antonio
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- NEXT Oncology /ID# 243007, San Antonio
- South Texas Accelerated Research Therapeutics (START) /ID# 276268, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology, San Antonio
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
Ap rekriteFaz 1
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, San Antonio
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Ap rekriteFaz 2
- Texas Oncology PA (San Antonio), San Antonio
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
- Grand Rapids, MI15 etid
Lòt etid nan San Antonio
- Kansè Poumon ki pa ti selil59 etid
- Kansè nan tete47 etid
- Kansè kolorektal46 etid
- Kansè Metastatik44 etid
- Kansè (tout kalite)41 etid
- Obèsite40 etid
- Dyabèt Tip 237 etid
- Sipwa34 etid
- Kansè ovè31 etid
- Kansè pankreyas31 etid
- Kansè pwostat28 etid
- Kansè Endomèt27 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.